Nachrichten zur Bristol-Myers Squibb Co. Aktie

Bristol-Myers Squibb Company declares $0.57 dividend

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Bristol Myers Squibb (BMY) Flat As Market Gains: What You Should Know

In the latest trading session, Bristol Myers Squibb (BMY) closed at $64.76, marking no change from the previous day....…

This Drug Candidate Could Be a Winner for Bristol Myers

Bristol Myers lung cancer drug candidate could be just months away from U.S. Food and Drug Administration approval....…

Bristol-Myers gets FDA approval for Devens cell therapy manufacturing facility

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Bristol Myers Squibb Facility Gets Commercial Production Approval From FDA

Bristol Myers Squibb Facility Gets Commercial Production Approval From FDA...…

Bristol Myers Squibb (BMY) Dips More Than Broader Markets: What You Should Know

Bristol Myers Squibb (BMY) closed at $65.16 in the latest trading session, marking a -0.49% move from the prior day....…

Bristol Myers (BMY) Announces Upbeat Data From NSCLC Study

Bristol Myers (BMY) reports encouraging four-year clinical efficacy results from its lung cancer study upon treatment with the combination immunotherapy…

OBI Pharma gibt Wechsel in der Geschäftsführung bekannt – Dr. Heidi Wang als Chief Executive Officer ernannt

Dr. Wang wurde vom Verwaltungsrat von OBI Pharma als Chief Executive Officer ernannt, um OBI Pharma mit der Vision zu…

The Zacks Analyst Blog Highlights NVIDIA, Bristol-Myers Squibb, ICICI Bank, Palo Alto and Walgreens Boots Alliance

NVIDIA, Bristol-Myers Squibb, ICICI Bank, Palo Alto and Walgreens Boots Alliance are included in this Analyst Blog....…

OBI Pharma Announces Executive Leadership Management Change – Heidi Wang, Ph.D. Appointed as Chief Executive Officer

Dr. Wang appointed by the OBI Pharma Board of Directors as Chief Executive Officer to lead OBI Pharma with a…

Bristol Myers Squibb (BMY) Gains But Lags Market: What You Should Know

Bristol Myers Squibb (BMY) closed the most recent trading day at $64.68, moving +0.37% from the previous trading session....…

Top Analyst Reports for NVIDIA, Bristol-Myers Squibb & ICICI Bank

Todays Research Daily features new research reports on 16 major stocks, including NVIDIA Corporation (NVDA), Bristol-Myers Squibb Company (BMY) and…

Bristol Myers (BMY) Loses 10.5% Year-to-Date: What Lies Ahead?

Bristol-Myers (BMY) top drugs, Revlimid and Eliquis, face challenges. It remains to be seen if the approval of new drugs…

Is Bristol Myers Squibb a Top Dividend Stock?

Its hefty yield isnt the only reason to consider buying this top pharma stock....…

Bristol Myers granted FDA priority review for lung cancer therapy

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Bristol Myers Gets FDA Priority Review of Repotrectinib in Certain Non-Small Cell Lung Cancer

Bristol Myers Gets FDA Priority Review of Repotrectinib in Certain Non-Small Cell Lung Cancer...…

Bristol Myers (BMY) Thrombosis Drug Gets Fast Track Designation

Bristol Myers (BMY) obtains Fast Track Designation from the FDA for milvexian, which is being developed in collaboration with Johnson…

Bristol Myers Opdivo gets EMA panel backing for expanded use in lung cancer

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Bristol Myers Squibb Gets CHMP Recommendation for Opdivo With Chemotherapy to Treat Lung Cancer

Bristol Myers Squibb Gets CHMP Recommendation for Opdivo With Chemotherapy to Treat Lung Cancer...…

Bristol Myers (BMY) Reports Pulmonary Fibrosis Study Results

Bristol Myers (BMY) idiopathic pulmonary fibrosis drug reduces the rate of lung function decline in a phase II study....…

Bristol-Myers pulmonary fibrosis candidate reduces lung decline rate

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Bristol Myers to Move BMS-986278 Into Phase 3 For Idiopathic Pulmonary Fibrosis

Bristol Myers to Move BMS-986278 Into Phase 3 For Idiopathic Pulmonary Fibrosis...…

Is Bristol-Myers Squibb Stock a Buy Now?

The stock faces risks, but are they outweighed by its low valuation?...…

3 Things About Bristol-Myers Squibb That Smart Investors Know

Its medium-term performance is going to rest on the acquisitions it makes today....…

Which Is the Better Passive Income Stock, Eli Lilly or Bristol Myers Squibb?

One offers more income today, and the other aims to offer more in the future....…

Insiderhandel: EVP & President, Research verkauft Aktien von Bristol-Myers Squibb Company im Wert von 3.378.818$

Vessey, Rupert - Vorstand - Tag der Transaktion: 2023-05-03...…

Form 8-K BRISTOL MYERS SQUIBB CO For: May 02

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

Immatics: Vertrauensbeweis von Bristol-Myers Squibb - Aktienanalyse

Kulmbach (www.aktiencheck.de) - Immatics-Aktienanalyse von "Der Aktionär": Michel Doepke vom Anlegermagazin "Der Aktionär" nimmt in einer aktuellen Aktienanalyse die Aktie von…

Deutsche Biotech-Hoffnung Immatics schießt über 30 Prozent hoch – die Hintergründe

Mit einem Kurssprung von gut 30 Prozent zählt die Aktie von Immatics am Dienstag zu den größten Gewinnern an der…

AbbVie, Bristol Myers Vied for Prometheus Before Merck Bought It

Um den gesamten Artikel unter news.google.com zu lesen, klicken Sie bitte auf die Überschrift...…

Zunehmende Konkurrenz für Krebsmedikament macht Pharmakonzern BMS zu schaffen

NEW YORK (dpa-AFX) - Der US-Pharmakonzern Bristol Myers Squibb (BMS) (Bristol-Myers Squibb) kämpft weiter mit zunehmender Konkurrenz für sein Blutkrebsmedikament…

Bristol Myers, Merck anemia therapy undergoes U.S. and EU review for label expansion

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Bristol Myers Gets FDA Priority Review for Expanded Reblozyl Use >BMY

Bristol Myers Gets FDA Priority Review for Expanded Reblozyl Use >BMY...…

Immatics gibt erstes Opt-in von Bristol Myers Squibb für TCR-T-Zelltherapiekandidaten aus aktueller strategischer Multi-Target-Kollaboration bekannt

Tübingen, Deutschland & Houston, Texas, 1. May 2023 – Immatics N.V. (NASDAQ: IMTX, „Immatics“), ein Unternehmen, das sich auf die…

Immatics Announces First Bristol Myers Squibb Opt-in of TCR-T Candidate from Ongoing Multi-target Strategic Collaboration

Tuebingen, Germany & Houston, May 1, 2023 – Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the…

dpa-AFX ProFeed